Unknown

Dataset Information

Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.


ABSTRACT:

Objective

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are new medications that improve cardiovascular and renal outcomes in patients with type 2 diabetes (T2D). However, the Food and Drug Administration has issued alerts regarding increased acute kidney injury (AKI) risk with canagliflozin and dapagliflozin. We aimed to assess the real-world risk of AKI in new SGLT2 inhibitor users in two large health care utilization cohorts of patients with T2D.

Research design and methods

We used longitudinal data from the Mount Sinai chronic kidney disease registry and the Geisinger Health System cohort. We selected SGLT inhibitor users and nonusers (patients with T2D without SGLT2 inhibitor prescription). We determined AKI by the KDIGO (Kidney Disease: Improving Global Outcomes) d

SUBMITTER: Nadkarni GN 

PROVIDER: S-EPMC5652593 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature